Enlivex Therapeutics Ltd. EPS Ratio | ENLV

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Enlivex Therapeutics Ltd.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
27	-0.73	-1.56	-1.69	-0.81	-0.9	-1.11	-1.4	-0.94	-1.01	1.08	-0.57	-0.14	-0.03	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
27	-1.69	1.23

Quarterly EPS Ratio Enlivex Therapeutics Ltd.

2025-Q4	2025-Q2	2024-Q4	2024-Q2	2023-Q4	2023-Q2	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
27	-0.08	-0.73	-0.16	-1.56	-0.37	-	-	-	-	-	-	-0.17	-	-	-	-0.23	-	-	-	-0.14	-	-	-	-	-	-	-	-	-	-0.19	-0.28	-0.22	-0.32	-0.34	-0.25	-0.26	-0.23	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
27	-1.56	1.27

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
Ionis Pharmaceuticals IONS	-1.41	$ 43.5	0.62 %	$ 6.96 B	USA
Agios Pharmaceuticals AGIO	-7.12	$ 31.25	0.88 %	$ 1.81 B	USA
Foghorn Therapeutics FHTX	-1.18	$ 2.0	0.74 %	$ 126 M	USA
Inhibikase Therapeutics IKT	-0.49	$ 2.0	0.5 %	$ 197 M	USA
Kamada Ltd. KMDA	0.35	$ 8.0	1.34 %	$ 461 M	Israel
Intellia Therapeutics NTLA	-3.81	$ 12.75	4.0 %	$ 1.38 B	USA
Ultragenyx Pharmaceutical RARE	-5.83	$ 14.5	3.19 %	$ 1.43 B	USA
Viridian Therapeutics VRDN	-5.31	$ 19.0	2.16 %	$ 1.93 B	USA
AbbVie ABBV	1.02	$ 265.76	1.12 %	$ 470 B	USA
AbCellera Biologics ABCL	-0.49	$ 13.78	0.29 %	$ 4.12 B	Canada
Abeona Therapeutics ABEO	1.34	$ 5.11	1.59 %	$ 271 M	USA
Arbutus Biopharma Corporation ABUS	-0.17	$ 4.67	4.94 %	$ 895 M	Canada
ACADIA Pharmaceuticals ACAD	2.32	$ 20.11	0.8 %	$ 3.39 B	USA
Achieve Life Sciences ACHV	-1.25	$ 7.01	0.13 %	$ 306 M	USA
AC Immune SA ACIU	-0.7	$ 2.71	0.55 %	$ 273 M	Schweiz
Aclaris Therapeutics ACRS	-0.53	$ 4.27	0.79 %	$ 523 M	USA
Adagene ADAG	-0.3	$ 2.8	0.28 %	$ 165 M	China
ADC Therapeutics SA ADCT	-1.12	$ 1.23	8.85 %	$ 156 M	Schweiz
Adial Pharmaceuticals ADIL	-11.9	$ 4.35	5.58 %	$ 2.91 M	USA
ADMA Biologics ADMA	0.62	$ 10.11	4.01 %	$ 2.41 B	USA
Adaptive Biotechnologies Corporation ADPT	-0.39	$ 29.84	5.26 %	$ 4.53 B	USA
Agenus AGEN	-10.6	$ 8.73	4.43 %	$ 260 M	USA
AIM ImmunoTech AIM	-8.62	$ 0.19	5.56 %	$ 308 K	USA
Akebia Therapeutics AKBA	-0.02	$ 0.91	5.26 %	$ 234 M	USA
Akari Therapeutics, Plc AKTX	-0.09	$ 8.76	0.46 %	$ 590 B	Britain
Aldeyra Therapeutics ALDX	-0.56	$ 0.92	4.88 %	$ 55.3 M	USA
Alector ALEC	-1.39	$ 1.99	9.94 %	$ 205 M	USA
Aligos Therapeutics ALGS	-2.45	$ 5.4	0.36 %	$ 53.4 M	USA
Alkermes plc ALKS	1.47	$ 42.76	2.42 %	$ 7.04 B	Irlanda
Allogene Therapeutics ALLO	-0.87	$ 1.5	0.33 %	$ 331 M	USA
Alnylam Pharmaceuticals ALNY	2.39	$ 219.89	0.08 %	$ 28.8 B	USA
Altimmune ALT	-1	$ 2.67	0.36 %	$ 235 M	USA
ALX Oncology Holdings ALXO	-1.9	$ 1.21	1.23 %	$ 64.9 M	USA
Amgen AMGN	14.3	$ 402.98	0.08 %	$ 217 B	USA
Amphastar Pharmaceuticals AMPH	2.1	$ 25.37	0.39 %	$ 1.19 B	USA
Amarin Corporation plc AMRN	-0.09	$ 12.09	0.31 %	$ 5.02 B	Irlanda
Amneal Pharmaceuticals AMRX	0.23	$ 20.35	0.25 %	$ 6.38 B	USA
AnaptysBio ANAB	4.52	$ 49.2	1.38 %	$ 1.43 B	USA
Anika Therapeutics ANIK	-0.76	$ 19.73	3.3 %	$ 283 M	USA
ANI Pharmaceuticals ANIP	3.5	$ 72.58	0.55 %	$ 1.46 B	USA
Annexon ANNX	-1.34	$ 4.2	0.24 %	$ 651 M	USA
Annovis Bio ANVS	-1.4	$ 1.2	1.69 %	$ 24.7 M	USA
Aprea Therapeutics APRE	-1.93	$ 0.68	0.16 %	$ 4.45 M	USA
Aptevo Therapeutics APVO	-87.3	$ 1.8	2.27 %	$ 568 K	USA
Aquestive Therapeutics AQST	-0.78	$ 4.57	0.44 %	$ 489 M	USA
Arcturus Therapeutics Holdings ARCT	-2.4	$ 14.66	12.51 %	$ 401 M	Israel
Ardelyx ARDX	-0.26	$ 3.39	1.5 %	$ 817 M	USA
argenx SE ARGX	21.1	$ 912.87	1.28 %	$ 56 B	Niderland
Armata Pharmaceuticals ARMP	-4.8	$ 3.66	3.98 %	$ 133 M	USA
Arcutis Biotherapeutics ARQT	-0.13	$ 25.15	0.04 %	$ 3.2 B	USA